UNLABELLED: There exists a worldwide shortage of donor livers available for orthotropic liver transplantation and hepatocyte transplantation therapies. In addition to their therapeutic potential, primary human hepatocytes facilitate the study of molecular and genetic aspects of human hepatic disease and development and provide a platform for drug toxicity screens and identification of novel pharmaceuticals with potential to treat a wide array of metabolic diseases. The demand for human hepatocytes, therefore, heavily outweighs their availability. As an alternative to using donor livers as a source of primary hepatocytes, we explored the possibility of generating patient-specific human hepatocytes from induced pluripotent stem (iPS) cells. CONCLUSION: We demonstrate that mouse iPS cells retain full potential for fetal liver development and describe a procedure that facilitates the efficient generation of highly differentiated human hepatocyte-like cells from iPS cells that display key liver functions and can integrate into the hepatic parenchyma in vivo.
UNLABELLED: There exists a worldwide shortage of donor livers available for orthotropic liver transplantation and hepatocyte transplantation therapies. In addition to their therapeutic potential, primary human hepatocytes facilitate the study of molecular and genetic aspects of humanhepatic disease and development and provide a platform for drug toxicity screens and identification of novel pharmaceuticals with potential to treat a wide array of metabolic diseases. The demand for human hepatocytes, therefore, heavily outweighs their availability. As an alternative to using donor livers as a source of primary hepatocytes, we explored the possibility of generating patient-specific human hepatocytes from induced pluripotent stem (iPS) cells. CONCLUSION: We demonstrate that mouseiPS cells retain full potential for fetal liver development and describe a procedure that facilitates the efficient generation of highly differentiated human hepatocyte-like cells from iPS cells that display key liver functions and can integrate into the hepatic parenchyma in vivo.
Authors: Eric Chiao; Menashe Elazar; Yi Xing; Anming Xiong; Muriel Kmet; Maria T Millan; Jeffrey S Glenn; Wing H Wong; Julie Baker Journal: Stem Cells Date: 2008-06-05 Impact factor: 6.277
Authors: Ajay Madan; Richard A Graham; Kathleen M Carroll; Daniel R Mudra; L Alayne Burton; Linda A Krueger; April D Downey; Maciej Czerwinski; Jameson Forster; Maria D Ribadeneira; Liang-Shang Gan; Edward L LeCluyse; Karl Zech; Philmore Robertson; Patrick Koch; Lida Antonian; Greg Wagner; Li Yu; Andrew Parkinson Journal: Drug Metab Dispos Date: 2003-04 Impact factor: 3.922
Authors: Jeffrey F Waring; Rita Ciurlionis; Robert A Jolly; Matthew Heindel; Gerry Gagne; Jane A Fagerland; Roger G Ulrich Journal: Toxicol In Vitro Date: 2003 Oct-Dec Impact factor: 3.500
Authors: David C Hay; Judy Fletcher; Catherine Payne; John D Terrace; Ronald C J Gallagher; Jan Snoeys; James R Black; Davina Wojtacha; Kay Samuel; Zara Hannoun; Anne Pryde; Celine Filippi; Ian S Currie; Stuart J Forbes; James A Ross; Philip N Newsome; John P Iredale Journal: Proc Natl Acad Sci U S A Date: 2008-08-21 Impact factor: 11.205
Authors: Yue Yu; James E Fisher; Joseph B Lillegard; Brian Rodysill; Bruce Amiot; Scott L Nyberg Journal: Liver Transpl Date: 2012-01 Impact factor: 5.799